• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[皮肤恶性黑色素瘤的诊断:当前S3组织学和分子病理学指南建议]

[Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].

作者信息

Rose C

机构信息

Dermatopathologie Lübeck, Maria-Goeppert-Str. 5, 23562, Lübeck, Deutschland.

出版信息

Hautarzt. 2017 Sep;68(9):749-761. doi: 10.1007/s00105-017-4046-9.

DOI:10.1007/s00105-017-4046-9
PMID:28875289
Abstract

The updated S3 guidelines on malignant melanoma were established in August 2016. The principles of diagnostics and classification are based on the histopathological results from the primary tumor and if necessary the sentinel lymph nodes. The most important factor for prognosis is the tumor thickness according to Breslow and the detection of sentinel node micrometastases. The surgical safety margin after excision is dependent on the tumor thickness. Furthermore, ulceration of the primary tumor and presence of mitosis in melanomas less than 1 mm in thickness are also considered in the T‑classification. The sentinel lymph nodes should be prepared according to established procedures using HE staining and immunohistochemical methods. The largest tumor diameter of a micrometastasis should be measured in tenths of a millimeter (Rotterdam classification). Molecular pathology testing for mutations in the BRAF and NRAS oncogenes should be carried out in patients with metastatic disease or surgically non-resectable tumors. In addition c-KIT mutations should be tested in acral lentiginous and mucosal melanomas. Treatment with signal transduction inhibitors is possible when mutations have been detected.

摘要

2016年8月制定了最新的恶性黑色素瘤S3指南。诊断和分类原则基于原发肿瘤以及必要时前哨淋巴结的组织病理学结果。预后的最重要因素是根据 Breslow 测量的肿瘤厚度以及前哨淋巴结微转移的检测情况。切除术后的手术安全切缘取决于肿瘤厚度。此外,T分类中还会考虑原发肿瘤的溃疡情况以及厚度小于1毫米的黑色素瘤中的有丝分裂情况。应按照既定程序使用苏木精-伊红染色和免疫组化方法制备前哨淋巴结。微转移灶的最大肿瘤直径应以十分之一毫米为单位测量(鹿特丹分类)。对于转移性疾病或手术不可切除肿瘤的患者,应进行BRAF和NRAS致癌基因的分子病理学检测。此外,对于肢端雀斑样痣型和黏膜黑色素瘤,应检测c-KIT突变。检测到突变时可使用信号转导抑制剂进行治疗。

相似文献

1
[Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].[皮肤恶性黑色素瘤的诊断:当前S3组织学和分子病理学指南建议]
Hautarzt. 2017 Sep;68(9):749-761. doi: 10.1007/s00105-017-4046-9.
2
[Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].[皮肤恶性黑色素瘤的诊断:当前S3组织学和分子病理学指南建议]
Pathologe. 2017 Feb;38(1):49-61. doi: 10.1007/s00292-016-0260-y.
3
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.基于证据和多学科共识的德国黑色素瘤诊疗指南:黑色素瘤的诊断与监测
Melanoma Res. 2007 Dec;17(6):393-9. doi: 10.1097/CMR.0b013e3282f05039.
4
Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice.根据 2009 年 AJCC 分类的恶性黑素瘤的组织病理学诊断:文献复习及对全科医学的建议。
J Dtsch Dermatol Ges. 2011 Sep;9(9):690-9. doi: 10.1111/j.1610-0387.2011.07714.x. Epub 2011 Jun 9.
5
Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?T1期(薄型)黑色素瘤的前哨淋巴结活检:有必要吗?
Ann Plast Surg. 2003 Jun;50(6):601-6. doi: 10.1097/01.SAP.0000069065.00486.1E.
6
Sentinel node identification by scintigraphic methods in cutaneous melanoma.通过闪烁显像法识别皮肤黑色素瘤中的前哨淋巴结
J Exp Clin Cancer Res. 2005 Jun;24(2):181-5.
7
Validity of ultrasound-guided aspiration needle biopsy in the diagnosis of micrometastases in sentinel lymph nodes in patients with cutaneous melanoma.超声引导下细针穿刺活检在皮肤黑色素瘤患者前哨淋巴结微转移诊断中的有效性
Vojnosanit Pregl. 2016 Oct;73(10):934-40. doi: 10.2298/VSP150227042S.
8
[Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].[美国癌症联合委员会(AJCC)皮肤黑色素瘤新分类的经验]
J Dtsch Dermatol Ges. 2005 Aug;3(8):592-8. doi: 10.1111/j.1610-0387.2005.05051.x.
9
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.黑色素瘤前哨淋巴结活检及选择性淋巴结清扫术后的初始复发模式及预后
Plast Reconstr Surg. 2003 Aug;112(2):486-97. doi: 10.1097/01.PRS.0000070989.23469.1F.
10
[Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].[前哨淋巴结活检对恶性黑色素瘤患者的重要预后意义]
Ned Tijdschr Geneeskd. 2004 May 1;148(18):884-8.

引用本文的文献

1
[Fluorescence detection to diagnose melanoma : An alternative objective method for dermatohistology].[荧光检测诊断黑色素瘤:皮肤组织学的一种替代客观方法]
Dermatologie (Heidelb). 2023 Sep;74(9):725-729. doi: 10.1007/s00105-023-05182-x. Epub 2023 Jun 23.
2
Dermoscopy and Reflectance Confocal Microscopy to Estimate Breslow Index and Mitotic Rate in Primary Melanoma.皮肤镜检查和反射式共聚焦显微镜检查用于评估原发性黑色素瘤的 Breslow 指数和有丝分裂率。
Dermatol Pract Concept. 2022 Oct 1;12(4):e2022174. doi: 10.5826/dpc.1204a174. eCollection 2022 Nov.

本文引用的文献

1
Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der Immunhistologie.原发性黑色素瘤中的米托司特:HE切片及免疫组织化学检查中的观察者间和观察者内可重复性
J Dtsch Dermatol Ges. 2016 Sep;14(9):910-6. doi: 10.1111/ddg.12797_g.
2
Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms.免疫治疗中的检查点抑制剂:恶性黑色素瘤治疗的一个里程碑。
J Dtsch Dermatol Ges. 2016 Jul;14(7):685-97. doi: 10.1111/ddg.13012_g.
3
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom.
转移性黑色素瘤中CTLA-4和PD1抗体免疫检查点阻断的副作用管理
J Dtsch Dermatol Ges. 2016 Jul;14(7):662-83. doi: 10.1111/ddg.13047_g.
4
[Molecular and immunohistochemical diagnostics in melanoma].[黑色素瘤的分子与免疫组化诊断]
Hautarzt. 2016 Jul;67(7):511-8. doi: 10.1007/s00105-016-3807-1.
5
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.前哨淋巴结活检阳性黑色素瘤患者完全淋巴结清扫与不清扫(DeCOG-SLT):一项多中心、随机、III 期临床试验。
Lancet Oncol. 2016 Jun;17(6):757-767. doi: 10.1016/S1470-2045(16)00141-8. Epub 2016 May 5.
6
Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy.完整切除活检后广泛局部切除(WLE)标本中残留黑色素瘤的频率。
J Am Acad Dermatol. 2016 Jan;74(1):102-7. doi: 10.1016/j.jaad.2015.08.065. Epub 2015 Oct 23.
7
Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.伴有分化标志物完全缺失的转移性恶性黑色素瘤(未分化/去分化黑色素瘤):14例患者分析,强调表型可塑性及分子检测作为替代诊断标志物的价值
Am J Surg Pathol. 2016 Feb;40(2):181-91. doi: 10.1097/PAS.0000000000000527.
8
Skin Cancer Screening in Germany. Documenting Melanoma Incidence and Mortality From 2008 to 2013.德国的皮肤癌筛查。记录2008年至2013年黑色素瘤的发病率和死亡率。
Dtsch Arztebl Int. 2015 Sep 18;112(38):629-34. doi: 10.3238/arztebl.2015.0629.
9
[Histological spectrum of malignant melanoma].[恶性黑色素瘤的组织学谱]
Pathologe. 2015 Feb;36(1):53-61. doi: 10.1007/s00292-014-2001-4.
10
[Sentinel lymph node biopsy and its diagnostic and therapeutic importance].[前哨淋巴结活检及其诊断和治疗意义]
Hautarzt. 2014 Nov;65(11):981-2. doi: 10.1007/s00105-014-3522-8.